Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi comments on otitis media guidance

Executive Summary

Sanofi-Aventis was the only company to submit comments on FDA's Acute Bacterial Otitis Media draft guidance. The company initiated its own pediatric-specific program in ABOM in 2002, and its comments, the company said, "come from practical and recent experience." Sanofi cautioned that there are challenges in conducting superiority trials in that the enrollment of patients with sufficient morbidity to demonstrate treatment effect in placebo-controlled studies may not be possible. Sanofi also said the guidance should make clear the relationship between criteria for enrollment and outcomes, and that the methodology to manage the uncertainty in clinical diagnosis in large studies, where tympanocentesis on all patients cannot be performed, needs to be addressed



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts